Cancer Care & Your Kidneys: A 2024 Guide to Protecting Renal Health During Chemotherapy
"Navigate cancer treatment with confidence. Understand how chemotherapy can impact your kidneys and discover actionable strategies for protecting your renal health."
Advances in cancer treatments have significantly improved patient outcomes, but many of these therapies, especially chemotherapy, can have unintended side effects. One major concern is nephrotoxicity, or kidney damage, which can disrupt treatment and diminish quality of life. This has led to the growing field of onco-nephrology, which focuses on managing kidney health in cancer patients.
This guide offers essential insights on preventing and treating renal injuries during cancer chemotherapy. By staying informed and proactive, you can protect your kidneys, maintain your treatment plan, and improve your overall well-being.
Understanding the delicate balance between fighting cancer and safeguarding your kidneys is key. This article is designed to help you navigate that balance with confidence.
Kidney Injury and Cancer Care
A 2024 review describes chemotherapy-induced acute kidney injury (AKI) as a significant challenge at the intersection of oncology and nephrology, particularly with platinum compounds. It also notes that kidney involvement leaves patients with cancer especially vulnerable, with higher morbidity and mortality than among patients without kidney problems. These sources describe the clinical impact but do not provide a general incidence figure for chemotherapy-related kidney injury.
Assessment and Individualized Treatment
A 2025 review describes adjusting cancer-treatment doses according to renal function, with particular considerations for patients on dialysis or with proteinuria. A separate consensus source recommends a personalized kidney health assessment to inform susceptibility to acute kidney disease, nephrotoxin stewardship, and individualized prevention and management. Together, these sources describe approaches that tailor treatment and kidney-risk management to the patient.
A Review of Modern Cancer Therapy and the Kidney
A comprehensive review published June 1, 2026, outlines kidney-related complications linked to modern cancer therapies. It also describes underlying pathophysiological mechanisms. The review highlights approaches to evaluating kidney function and mitigating risk.
Understanding Chemotherapy's Impact on Kidney Function
Chemotherapy drugs, while targeting cancer cells, can also affect the kidneys, leading to a range of issues. Some drugs cause direct damage to kidney cells, while others disrupt blood flow or cause inflammation. Recognizing these potential risks is the first step in protecting your kidney health.
- Pre-existing Kidney Conditions: If you already have kidney disease, you’re more vulnerable.
- Specific Chemotherapy Drugs: Some drugs, like cisplatin, are particularly harsh on the kidneys.
- High Doses: Higher doses increase the risk of kidney damage.
- Age: Older adults may have reduced kidney function, making them more susceptible.
- Dehydration: Insufficient fluid intake can concentrate drugs in the kidneys, increasing harm.
- Other Health Issues: Conditions like diabetes, high blood pressure, and heart disease can compound the risk.
Limits of Evidence and Diagnostic Tests
A systematic review and meta-analysis of long-term cisplatin nephrotoxicity after childhood cancer reported that marked methodological heterogeneity impeded its analysis. Separately, a review of AKI diagnosis in patients with cancer says traditional tools—including creatinine- and cystatin C–based eGFR, urinalysis, urine sediment, protein quantification, and urine electrolyte measurement—lack the sensitivity and specificity to distinguish among underlying AKI causes. These limitations complicate both synthesis of research findings and identification of AKI etiology.
Different Outcomes and Evidence Formats
The 2016 guidelines report that AKI occurred in 36% of 537 patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who underwent induction chemotherapy. They also report that 61.7% of patients who developed end-stage renal disease (ESRD) died; this is a different outcome and denominator from the AKI figure. A case-based resource complements these figures by covering kidney-disease mechanisms and management in cancer patients, including chemotherapy toxicity and transplantation-related concerns.
Empowering Your Journey Through Informed Action
Managing kidney health during chemotherapy requires a multifaceted approach. By staying informed, working closely with your healthcare team, and adopting proactive strategies, you can minimize risks and maintain your quality of life throughout your cancer treatment journey. Remember, you are not alone, and support is available every step of the way.
Integrating Kidney Expertise into Oncology
A 2025 editorial identifies integration of nephrology expertise into oncology practice as a challenge, including management of treatment-related nephrotoxicity and understanding the molecular basis of kidney involvement in cancer. An onconephrology update describes tools for understanding mechanisms, diagnostic workup, and treatment options for kidney effects in patients with cancer. It presents these resources as a way to help improve outcomes, while the editorial underscores that integration and mechanistic understanding remain challenges.